To report the first documented clinical use of lenalidomide as maintenance therapy for metastatic follicular dendritic cell sarcoma (FDCS) following chemotherapy, highlighting its innovative potential.
Key Findings:
The patient achieved nearly total sustained remission with lenalidomide for approximately seven years, with only one manageable recurrence noted during the treatment period.
Interpretation:
Lenalidomide appears to be a promising maintenance therapy for metastatic FDCS, particularly in cases where conventional treatments are ineffective, potentially due to its immunomodulatory effects.
Limitations:
This is a single case study, limiting generalizability.
Long-term effects and optimal dosing of lenalidomide in FDCS remain unclear, highlighting the need for larger studies.
Conclusion:
Lenalidomide may provide a well-tolerated and effective maintenance treatment option for patients with metastatic FDCS, warranting further investigation to confirm these findings.
